SOUTH PLAINFIELD, N.J. and SAN DIEGO – Oct. 6, 2016 – GENEWIZ, a leading global genomics services provider, today announced it will implement multiple Edico Genome DRAGEN™ Bio-IT Processors to accelerate the analysis of massive volumes of genomic data generated by its high-throughput sequencing platforms. GENEWIZ’s already quick turnaround times are expected to be reduced by days for large next-generation sequencing (NGS) data sets, without sacrificing data quality or integrity.
With the adoption of the DRAGEN processors on GENEWIZ’s industry-leading, high-throughput platform, specifically the Illumina® HiSeq X™ Ten for whole genomes, customers will receive results in an unprecedented short amount of time. DRAGEN runs numerous highly optimized hardware-accelerated analysis algorithms that significantly expedite the analysis of large NGS data.
“The HiSeq X Ten is the highest throughput sequencing platform on the market with an unparalleled scale for whole genome sequencing, and offering the instrument to our customers supports countless areas of research and applications,” said Ethan Ge, chief information officer at GENEWIZ. “By adding DRAGEN to our workflow, we’re able to process the sizable amounts of data coming off these sequencers many times faster to accelerate our customers’ research projects and discoveries.”
GENEWIZ’s broad genomics services offering includes NGS, Sanger DNA sequencing, gene synthesis and molecular biology, available on a breadth of cutting-edge sequencing platforms including the Illumina HiSeq X Ten, Pacific Biosciences Sequel™ System and 10x Genomics® Chromium™.
“GENEWIZ is known for its best-in-class business model, dedicated customer engagement and visionary leadership, which contributes to the company being one of the fastest growing genomics services providers in the world,” said Pieter van Rooyen, Ph.D., chief executive officer of Edico Genome. “With the addition of DRAGEN we look forward to supporting GENEWIZ’s accelerated growth and further improving their customer offerings.”
DRAGEN is highly reconfigurable, using a field-programmable gate array (FPGA) to provide hardware-accelerated implementations of genome pipeline algorithms, such as BCL conversion, compression, mapping, alignment, sorting, duplicate marking and haplotype variant calling. The platform includes whole genome and exome, transcriptome, joint genotyping, methylation, and GATK pipelines, and allows users to develop custom algorithms as well as refine and improve existing pipelines. Updated versions are made available for customers through simple remote downloads.
GENEWIZ is a global leader in genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in DNA sequencing, gene synthesis, molecular biology, high throughput sequencing, bioinformatics, and GLP regulatory-compliant services.
Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a global network of laboratories in Boston, MA; Washington, DC Metro; Research Triangle Park, NC; San Diego, CA; Los Angeles, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, China; Suzhou, China; London, United Kingdom; and Tokyo, Japan. For more information, visitwww.genewiz.com, and connect with us on LinkedIn, Twitter, Facebook, YouTube, and Weibo.
About Edico Genome
Edico Genome has created the world’s first bioinformatics processor designed to analyze next-generation sequencing data, DRAGEN™. The use of next-generation sequencing is growing at an unprecedented pace, creating a need for a technology that can process this big data rapidly and accurately. Edico Genome’s computing platform has been shown to speed whole genome data analysis from hours to minutes, while maintaining high accuracy and reducing costs, enabling clinicians and researchers to reveal answers more quickly. For more information, visit http://www.EdicoGenome.com or follow @EdicoGenome.